NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Arvinas has announced positive biomarker, pharmacokinetic and pharmacodynamic data from two Phase I studies assessing ARV-102, an oral investigational PROTAC degrader of leucine-rich repeat kinase 2 ...
– Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation ...
NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
NEW HAVEN, Conn., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Date & Time: Oct. 8, 12:00–1:00 p.m. HST Presentation order: 11 Poster Number: Late Breaker Abstract 22 Additional information including abstracts can be found on the MDS 2025 website. About ARV-102 ...
(MENAFN- GlobeNewsWire - Nasdaq) – ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson's disease – – ARV-102 demonstrated dose-dependent cerebrospinal ...
– After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results